Drug intelligence / Profile preview

GXNPC1

Development stage: Phase 2
Lead developer: Gwo Xi Stem Cell Applied Technology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

GXNPC1 is an autologous adipose-derived stem cell (ADSC) therapy developed by Gwo Xi Stem Cell Applied Technology for the treatment of chronic stroke. The therapy involves the surgical transplantation of a patient's own adipose-tissue derived stem cells into the brain tissue surrounding an ischemic infarct (peri-infarct area). This regenerative medicine approach is designed to promote neural repair and functional recovery in adult patients (typically aged 65-80) who have suffered a chronic non-hemorrhagic stroke more than six months prior. The treatment aims to leverage the paracrine and regenerative potential of mesenchymal stem cells to improve neurological outcomes.

Brand names: GXNPC1GXNPC-1GXNPC 1
Other names: Adipose-Derived Stem CellsADSCsautologous ADSCs

Beyond the preview

Go deeper on GXNPC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GXNPC1.

Explore the full profile